莫西沙星序贯治疗社区获得性肺炎的疗效及经济学评价

目的:观察两种不同给药方案治疗社区获得性肺炎观察疗效及经济学评价。方法:对我院70例患者随机分为两组,序贯治疗组和对照组(全程静脉滴注),每组35例。序贯治疗组给予莫西沙星注射液400mg,静脉滴注,1次d-1,7d,病情好转后,改为莫西沙星片400mg,口服,1次d-1,5d,共12d。对照组给予莫西沙星注射液400mg,静脉滴注,1次d-1,12d。结果:序贯组和对照组治愈率分别为60.6%,65.7%(P>0.05),有效率达88.6%,91.4%(P>0.05),序贯治疗组的成本-效果比为2993,低于对照组的4149。结论:在社区获得性肺炎疗效观察中莫西沙星治疗安全有效,序贯疗法可减少患者的医疗费用,首选治疗方案推荐莫西沙星序贯治疗。

Objective:To observe two different dosing regimens for the treatment of community acquired pneumonia curative effect observation and economics evaluation. Methods:70 patients were randomly divided into two groups, sequential therapy group and the control group (total intravenousdrip), 35 cases of each group. Sequential therapy group were givenmoxifloxacin injection 400mg, intravenous drip, 1 times D-1, 7d, improved, changed to moxifloxacin tablets 400mg, oral, 1 times D-1, 5D, 12D. The control group was given moxifloxacin injection 400mg, intravenous drip, 1 times D-1, 12D. Results:the sequential group and the control group, the cure rate is respectively 60.6%, 65.7% (P > 0.05), the effective rate was 88.6%, 91.4% (P > 0.05), sequential therapy group cost-effectiveness ratiowas 2993, lower than that of the control group 4149. Conclusions:moxifloxacin therapy is safe and effective curative effect observation of pneumonia in the community, sequential therapy can reduce the medical costs of the patients, the treatment of moxifloxacin sequential therapy is recommended.